Astrocyte Pharmaceuticals

Venture-backed company · Series B
Rounds on record
1
Latest round
Sep 30, 2026
Series B
Latest round size
$9.5M
More
Ask DFX about thisView relationshipsFinancing historyInvestorsOwnership and outcomes
As of · the latest observation of this company; each round carries its own date

1 additional investor

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

  1. $9.5M
    announced

    Announced a Series B ($9.5M round) on 30 Sep 2026.

    A company that just raised has fresh capital, a new board and new vendors to choose.

    FactPress release wires (PR Newswire, GlobeNewswire)For Investors, lenders, service providersFinancing history →
  2. 4 investors
    named

    4 investors on record; Deepwork Capital led a round.

    The investors already on the cap table shape who leads the next round.

    Factfunding announcements, portfolio pages and Form DFor Investors, foundersInvestors →
Drawing the relationship network…

Facts

Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$9.5Msum of rounds with a disclosed amount only
Named investors
4

Financing history

1 round
  1. Sep 30, 2026
    Series B · $9.5M (disclosed)
    Deepwork Capital, LLC (lead)Waterstar (participant)Dynagrow Capital (participant)Angel Star Ventures (participant)
    Fact Press release · “Astrocyte Pharmaceuticals Secures $9.5 Million Series B to Advance Phase 2 Clinical Development of Breakthrough TBI and Concussion Therapy AST-004”

Investors on record

4 edges

Ownership and outcomes

none on record
Outcome stated by investors

No firm portfolio page lists this company, so no outcome is stated.

No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.

Credit relationships

none on record
No lender position matched to this company.

People

0 officers, 0 directors
No officer or director on record.

Timeline

1 event
  1. Sep 30, 2026
    Astrocyte Pharmaceuticals announced Series B of $9,500,000, led by DeepWork Capital
    Round announced Fact Press release

Evidence

1 observation
Every observation on this company
  • Round announced: Series B $9,500,000 Sep 30, 2026 Fact Press release

Investors it fits

25 scored matches, best firstas of
  • score 38.5confidence 80%
    Why: stage fit; activity
  • score 35.7confidence 80%
    Why: stage fit; activity
  • score 35.7confidence 80%
    Why: stage fit; activity

+22 more investors it fits

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

Scored by DFX match engines from the record's observed portfolio, stage, geography and recent activity. A fit is a reason to look, not a mandate; the blockers say what the model could not confirm. Names and the evidence sentences show with the names on this page.

Record history

1 identity change, 1 dated event on the change ledger, latest event first
  • Event dated
    2026-09-30source on record
  • Round announced
    2026-09-30source on record

The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.